AVITA Medical appoints Cary Vance as permanent CEO, Jan Stern Reed as Board Chair

AVITA Medical, Inc.

Cary Vance named President and CEO effective April 30, 2026; served as Interim CEO since October 2025.
Jan Stern Reed appointed Chair of the Board; had been Lead Independent Director since October 2025.
Vance receives $702k base salary, 80% bonus target, and $3.354M in equity awards subject to stockholder approval.
Employment agreement: 3-year initial term; severance of 18 months base salary plus COBRA if terminated without cause.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jan Stern Reed

Chair of the Board

AVITA Medical, Inc.

Filed: May 01, 2026 23:59 UTC

while the Board appointed Jan Stern Reed as Chair of the Board while simultaneously terminating the Lead Independent Director position

Role change

Cary Vance

President and Chief Executive Officer

AVITA Medical, Inc.

Effective: 2026-04-30
Filed: May 01, 2026 23:59 UTC

On April 29, 2026, the Board of Directors (the “Board”) of AVITA Medical, Inc (the "Company") appointed Cary Vance as President and Chief Executive Officer ("CEO"), effective April 30, 2026

Source: SEC EDGAR

accession 0001193125-26-201662

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.